Abstract
The fan-associated pneumonia currently is a leading reason of mortality of patients in resuscitation and intensive care unit. Development of the disease is accompanied by serious clinical and economic consequences. The adequate antibacterial therapy plays the determining role in the favorable outcome in pneumonia. Doripemen is a new parenteral 1-beta-methyl-carbapenem that was launched into the pharmaceutical market of Russia in 2008. The purpose of this review is to generalize the results accumulated to this moment on effectiveness of doripenem in therapy of fan-associated pneumonia.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
